Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

NCT01724528 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

346

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor Lysis Syndrome

Interventions

DRUG: Febuxostat
DRUG: Allopurinol

Sponsor

Menarini Group